Jayanth Panyam

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2021
Publications (10 Years): 5

Top Topics

Inflammatory Response

Dendritic Cells

Squamous Cell Carcinoma

Top Venues

Scientific reports

Molecular pharmaceutics

The Journal of pharmacology and experimental therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Vidhi Khanna, Hyunjoon Kim, Wenqiu Zhang, Peter Larson, Manan Shah, Thomas S Griffith, David Ferguson, Jayanth Panyam
Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC). Scientific reports 11 (1) (2021)
Hyunjoon Kim, Vidhi Khanna, Tamara A Kucaba, Wenqiu Zhang, Drishti Sehgal, David M Ferguson, Thomas S Griffith, Jayanth Panyam
TLR7/8 Agonist-Loaded Nanoparticles Augment NK Cell-Mediated Antibody-Based Cancer Immunotherapy. Molecular pharmaceutics 17 (6) (2020)
Hyunjoon Kim, Thomas S Griffith, Jayanth Panyam
Poly(d,l-lactide-co-glycolide) Nanoparticles as Delivery Platforms for TLR7/8 Agonist-Based Cancer Vaccine. The Journal of pharmacology and experimental therapeutics 370 (3) (2019)
Stephen Kalscheuer, Vidhi Khanna, Hyunjoon Kim, Sihan Li, Deepali Sachdev, Arthur DeCarlo, Da Yang, Jayanth Panyam
Discovery of HSPG2 (Perlecan) as a Therapeutic Target in Triple Negative Breast Cancer. Scientific reports 9 (1) (2019)
Hyunjoon Kim, Vidhi Khanna, Tamara A Kucaba, Wenqiu Zhang, David M Ferguson, Thomas S Griffith, Jayanth Panyam
Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine. Molecular pharmaceutics 16 (3) (2019)